Dermatologists recommend adding an E to the ABCD acronym for recognizing early melanomas

NewsGuard 100/100 Score

One more letter should be added to the alphabetic list of warning signs of melanoma, a potentially deadly skin cancer, according to a group of NYU School of Medicine dermatologists and their Australian colleagues. Based on a review of the medical literature, they recommend adding the letter "E" -- for "evolving" -- to the first four letters of the alphabet that are already used widely to help physicians and adults identify suspicious moles on the skin.

Their report is published in the Dec. 8, 2004, issue of the Journal of the American Medical Association (JAMA).

Almost 20 years ago, a group of NYU dermatologists introduced the ABCD acronym for recognizing growths on the skin that could be early melanomas. They devised the rule based on many years of clinical experience, which taught them that early melanomas can be identified by their asymmetry, uneven borders, colors, and size.

The warning signs are: "A" for asymmetry; one half of a mole doesn't match the other half; "B" for border irregularity; the edges of a mole are ragged, notched or blurred; "C" for color; a non-uniform mixture of brown, black, red, white, or blue; and "D" for diameter greater than 6 millimeters, the size of a pencil eraser.

The ABCD rule has been helpful in identifying early melanoma. But now the original group of NYU dermatologists who devised the rule, along with some of their younger colleagues, recommends expanding the rule to recognize that early melanomas frequently change in appearance. This is especially true for a type of melanoma called nodular that doesn't fit neatly into the ABCD criteria, explains David Polsky, M.D., Ph.D., a dermatologist and one of the authors of the new report. Dr. Polsky is Associate Director of the NYU Department of Dermatology's Pigmented Lesions Section.

Nodular melanoma accounts for 10 to 15 percent of all melanomas. One of four basic types of melanomas, the nodular form is the most aggressive. But it frequently doesn't look suspicious, notes Dr. Polsky, because it may not have the ABC features of early melanomas. However, there are many reports in the medical literature that highlight the changing nature of these lesions, which is the most important clue to their diagnosis.

In a study of 125 patients cited in the JAMA report, for example, 78 percent of patients with nodular melanoma noted some kind of a change in the appearance of their lesion. Patients with other forms of melanoma in the study also noted a change the appearance of their lesion. Moreover, in another cited study of 169 pigmented lesions, dermatologists noted that the lesions that had changed were at least four times more likely to be melanoma than the lesions that did not change.

"An evolving lesion is one which is changing in terms of the five S's -- size, shape, symptoms such as itching or tenderness, surface bleeding, or shades of color," says Dr. Polsky. "Essentially, a lesion that significantly changes is a concerning lesion."

The incidence of melanoma continues to rise. This year it is expected to strike 55,100 people in the United States, and some 7,910 people with the disease are expected to die, according to the American Cancer Society. Excessive exposure to sunlight, a fair complexion, a family history of melanoma, and numerous moles, among other factors, place people at higher risk for developing the disease. With early detection and prompt treatment, however, melanoma is highly curable.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment